Get started
Author

Ntlotlang Mokgautsi

Observed name: Mokgautsi Ntlotlang
ORCID: 0000-0003-2076-9768
Observed ORCID: 0000-0003-2076-9768
OpenAlex ID: A5089617153
mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications
2021 · Bashir Lawal, Ching-Yu Lee, et al. · Frontiers in Oncology · 52
PDF
Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines
2021 · Bashir Lawal, Yen-Lin Liu, et al. · Biomedicines · 52
PDF
EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer
2020 · Shian-Ren Lin, Yu-Ching Wen, et al. · Oncogene · 42
HNC0014, a Multi-Targeted Small-Molecule, Inhibits Head and Neck Squamous Cell Carcinoma by Suppressing c-Met/STAT3/CD44/PD-L1 Oncoimmune Signature and Eliciting Antitumor Immune Responses
2020 · Jih-Chin Lee, Alexander T.H. Wu, et al. · Cancers · 38
PDF
Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis
2020 · Shian-Ren Lin, Ntlotlang Mokgautsi, et al. · Molecules · 28
PDF
Network Pharmacological Analysis through a Bioinformatics Approach of Novel NSC765600 and NSC765691 Compounds as Potential Inhibitors of CCND1/CDK4/PLK1/CD44 in Cancer Types
2021 · Ntlotlang Mokgautsi, Yu-Chi Wang, et al. · Cancers · 27
PDF
An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3β/β-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties
2021 · Ntlotlang Mokgautsi, Ya-Ting Wen, et al. · International Journal of Molecular Sciences · 27
PDF
Gamma-mangostin isolated from garcinia mangostana suppresses colon carcinogenesis and stemness by downregulating the GSK3β/β-catenin/CDK6 cancer stem pathway
2021 · Alexander TH Wu, Yuan-Chieh Yeh, et al. · Phytomedicine · 26
In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1
2021 · Harshita Nivrutti Khedkar, Yu-Chi Wang, et al. · International Journal of Molecular Sciences · 24
PDF
Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects
2021 · Tse-Hung Huang, Ntlotlang Mokgautsi, et al. · Cells · 18
PDF
Preclinical Repurposing of Sitagliptin as a Drug Candidate for Colorectal Cancer by Targeting CD24/CTNNB1/SOX4-Centered Signaling Hub
2024 · Jing-Wen Shih, Alexander T. H. Wu, et al. · International Journal of Molecular Sciences · 14
PDF
Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent
2023 · Harold A. Chinyama, Li Wei, et al. · International Journal of Molecular Sciences · 14
PDF
Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling
2022 · Wai-Hung Leung, Jing-Wen Shih, et al. · Biomedicines · 14
PDF
A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling
2021 · Alexander T. H. Wu, Hsu-Shan Huang, et al. · Cells · 14
PDF
In Vitro and In Silico Biological Studies of 4-Phenyl-2-quinolone (4-PQ) Derivatives as Anticancer Agents
2023 · Yi-Fong Chen, Bashir Lawal, et al. · Molecules · 11
PDF
Anticancer Activities of 9-chloro-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinolin-11-one (SJ10) in Glioblastoma Multiforme (GBM) Chemoradioresistant Cell Cycle-Related Oncogenic Signatures
2022 · Ntlotlang Mokgautsi, Yu-Cheng Kuo, et al. · Cancers · 10
PDF
A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.
2021 · Bashir Lawal, Wen-Cheng Lo, et al. · PubMed · 9
Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells
2024 · Harshini Mehta, Melvin Anyasi Ambele, et al. · Cells · 8
PDF
In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer
2023 · Lung-Ching Chen, Ntlotlang Mokgautsi, et al. · Biomedicines · 7
PDF
Multiomics Study of a Novel Naturally Derived Small Molecule, NSC772864, as a Potential Inhibitor of Proto-Oncogenes Regulating Cell Cycle Progression in Colorectal Cancer
2023 · Ntlotlang Mokgautsi, Yu-Cheng Kuo, et al. · Cells · 6
PDF
Structure-based design, synthesis and biological evaluation of N-substituted 6H-thiochromeno[2,3–c]quinolin-12(12H)-one as potential breast cancer drugs
2023 · Maryam Rachmawati Sumitra, Lung-Ching Chen, et al. · Arabian Journal of Chemistry · 4
In silico repurposing of midostaurin as a therapeutic candidate for head and neck cancer via targeting SPARC/MMP9/CD44 Cancer-Associated Fibroblasts (CAFs) oncogenic signature.
2023 · Kuan-Chou Lin, Chia-Che Wu, et al. · PubMed · 3
PDF
Deciphering the immuno-pathological role of FLT, and evaluation of a novel dual inhibitor of topoisomerases and mutant-FLT3 for treating leukemia.
2022 · Bashir Lawal, Yu-Cheng Kuo, et al. · PubMed · 3
In silico identifying MET/FN1/TGFBI as molecular targets in drug-resistant head and neck cancer and preclinical repurposing sulfasalazine for enhanced therapeutic efficacy
2023 · Ntlotlang Mokgautsi, Alexander TH Wu, et al. · Arabian Journal of Chemistry · 2
Correction: Leung et al. Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines 2022, 10, 377
2025 · Wai-Hung Leung, Jing-Wen Shih, et al. · Biomedicines · 1
PDF
Works count: 32
Citation count: 456
H-index: 14
I10-index: 16
Year
Topic
Type